レミケードの世界市場レポート 2025年：疫学、パイプライン分析、市場インサイトと予測

レミケード市場規模は、今後数年間で力強い成長が見込まれます。2029年には年間平均成長率（CAGR）5%で32億6,800万米ドルに成長します。予測期間の成長は、バイオシミラーの存在感の高まり、世界の疾病負担、新興国での市場拡大、規制や保険による支援、可処分所得の上昇などに起因すると考えられます。予測期間の主要動向には、バイオシミラーの採用、デジタルヘルス統合、個別化医療、生物学的療法の革新、ドラッグデリバリーシステムの改良などがあります。

自己免疫疾患の有病率の増加は、レミケード市場の成長を促進すると予想されます。自己免疫疾患は、免疫系が体内の細胞や組織、臓器を外敵と間違えて攻撃することで発症します。自己免疫疾患の増加は、遺伝的要因、環境の変化、汚染物質への暴露の増加、ライフスタイルの選択、診断能力の向上などの複合的な要因によるものと考えられています。レミケード（インフリキシマブ）は、関節リウマチ、クローン病、潰瘍性大腸炎などの疾患に関与する重要な炎症性サイトカインである腫瘍壊死因子α（TNF-a）を標的として阻害することにより、自己免疫疾患の治療に使用されます。例えば、米国疾病予防管理センター（CDC）が2024年2月に報告したところによると、2022年には18歳以上の成人の18.9％が関節炎と診断され、男性（16.1％）よりも女性（21.5％）の有病率が高かったです。また、有病率は年齢とともに増加し、18～34歳の3.6％から75歳以上の53.9％に達しました。このような自己免疫疾患の罹患率の増加は、レミケード市場の成長を後押しすると予想されます。

レミケード市場の注目すべき動向は、薬剤製剤の革新、特に皮下投与型薬剤の開発にますます焦点が当てられていることです。これらの製剤は、従来型静脈内治療に代わる迅速かつ簡便な代替手段を提供するため、患者の利便性向上、治療アドヒアランスの向上、市場アクセスの拡大をもたらします。例えば、2024年3月、Celltrion USA, Inc.は、FDAに承認された最初のインフリキシマブ皮下注製剤であるZymfentraを発売しました。Zymfentra（infliximab-dyyb）は、炎症性腸疾患（IBD）の一種である中等度から重度の活動性潰瘍性大腸炎（UC）とクローン病（CD）を有する成人の維持療法を適応としています。今回の承認により、インフリキシマブ静注製剤による前治療後の使用が可能となり、長期的な疾患管理により利便性の高い選択肢となります。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 バイオ医薬品市場における製品特性

• 分子タイプ
• 投与経路（ROA）
• 作用機序（MOA）
• 安全性と有効性

第4章 市場動向と戦略

第5章 市場：金利、インフレ、地政学的要因、新型コロナとその回復が市場に与える影響を含むマクロ経済シナリオ

第6章 世界の成長分析と戦略分析フレームワーク

• 世界のレミケード：PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界のレミケード市場：成長率分析
• 世界のレミケード市場の実績：規模と成長、2019～2024年
• 世界のレミケード市場の予測：規模と成長、2024～2029年、2034年
• 世界のレミケード：総潜在市場規模（TAM）

第7章 世界の価格分析と予測

第8章 市場セグメンテーション

• 世界のレミケード市場：疾患適応症別、実績と予測、2019～2024年、2024～2029年、2034年
• クローン病
• 関節リウマチ
• 強直性脊椎炎
• 乾癬性関節炎
• 潰瘍性大腸炎
• 尋常性乾癬
• 世界のレミケード市場：投与経路別、実績と予測、2019～2024年、2024～2029年、2034年
• 皮下
• 静脈内
• 非経口
• 世界のレミケード市場：最終用途別、実績と予測、2019～2024年、2024～2029年、2034年
• 病院
• クリニック
• 外来診療
• 在宅医療

第9章 臨床適応症の世界的疫学

• 薬剤の副作用
• 臨床適応症の発症率と有病率

第10章 地域別・国別分析

• 世界のレミケード市場：地域別、実績と予測、2019～2024年、2024～2029年、2034年
• 世界のレミケード市場：国別、実績と予測、2019～2024年、2024～2029年、2034年

第11章 アジア太平洋市場

第12章 中国市場

第13章 インド市場

第14章 日本市場

第15章 オーストラリア市場

第16章 韓国市場

第17章 西欧市場

第18章 英国市場

第19章 ドイツ市場

第20章 フランス市場

第21章 東欧市場

第22章 北米市場

第23章 米国市場

第24章 カナダ市場

第25章 南米市場

第26章 中東市場

第27章 アフリカ市場

第28章 競合情勢と企業プロファイル

• レミケード市場：競合情勢
• レミケード市場：企業プロファイル
  • Janssen BIoTech Inc.

第29章 世界市場：パイプライン分析

第30章 世界の市場競合ベンチマーキングとダッシュボード

第31章 主要な合併と買収

第32章 最近の市場動向

第33章 市場の潜在力が高い国、戦略

• レミケード市場、2029年：新たな機会を提供する国
• レミケード市場、2029年：新たな機会を提供するセグメント
• レミケード市場、2029年：成長戦略
  • 市場動向による戦略
  • 競合の戦略

第34章 付録

Remicade (infliximab) is a biologic medication classified as a tumor necrosis factor-alpha (TNF-a) inhibitor. It is used to treat autoimmune conditions such as rheumatoid arthritis, Crohn's disease, ulcerative colitis, psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis. By inhibiting TNF-a, a protein involved in inflammation, Remicade helps alleviate symptoms, slow disease progression, and improve quality of life.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The primary disease indications for remicade include Crohn's disease, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, ulcerative colitis, and plaque psoriasis. Crohn's disease is a chronic inflammatory disorder of the gastrointestinal tract, often causing symptoms such as abdominal pain, severe diarrhea, weight loss, and fatigue. Remicade can be administered through subcutaneous, intravenous, or parenteral routes, with the end users including hospitals, clinics, ambulatory care settings, and home care.

The remicade market research report is one of a series of new reports from The Business Research Company that provides remicade market statistics, including remicade industry global market size, regional shares, competitors with a remicade market share, detailed remicade market segments, market trends and opportunities, and any further data you may need to thrive in the remicade industry. This remicade market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The remicade market size is expected to see strong growth in the next few years. It will grow to $3,268 million in 2029 at a compound annual growth rate (CAGR) of 5%. The growth in the forecast period can be attributed to the rising presence of biosimilars, global disease burden, market expansion in emerging economies, regulatory and insurance support, and rising disposable income. Major trends in the forecast period include the adoption of biosimilars, digital health integration, personalized medicine, biologic therapy innovations, and improved drug delivery systems.

The increasing prevalence of autoimmune diseases is expected to drive the growth of the remicade market. Autoimmune diseases occur when the immune system mistakenly attacks the body's own cells, tissues, or organs, mistaking them for foreign invaders. The rise in autoimmune diseases is attributed to a combination of genetic factors, environmental changes, greater exposure to pollutants, lifestyle choices, and improved diagnostic capabilities. Remicade (infliximab) is used to treat autoimmune conditions by targeting and inhibiting tumor necrosis factor-alpha (TNF-a), a critical inflammatory cytokine involved in diseases such as rheumatoid arthritis, Crohn's disease, and ulcerative colitis. For example, the Centers for Disease Control and Prevention (CDC) reported in February 2024 that in 2022, 18.9% of adults aged 18 and older were diagnosed with arthritis, with a higher prevalence among women (21.5%) than men (16.1%). The prevalence also increased with age, ranging from 3.6% in individuals aged 18-34 to 53.9% in those aged 75 and above. This rising incidence of autoimmune diseases is expected to boost the growth of the remicade market.

A notable trend in the remicade market is the increasing focus on innovation in drug formulation, particularly with the development of subcutaneous versions of medications. These formulations offer improved patient convenience, better treatment adherence, and greater market accessibility, as they provide a quicker and easier alternative to traditional intravenous treatments. For example, in March 2024, Celltrion USA, Inc. launched Zymfentra, the first subcutaneous formulation of infliximab approved by the FDA. Zymfentra (infliximab-dyyb) is indicated for the maintenance therapy of adults with moderate-to-severe active ulcerative colitis (UC) and Crohn's disease (CD), both of which are forms of inflammatory bowel disease (IBD). The approval allows it to be used after prior treatment with an intravenous infliximab product, providing a more convenient option for long-term disease management.

In September 2024, Tharimmune Inc., a U.S.-based biopharmaceutical company, acquired a global license from Intract Pharma to develop an oral version of infliximab, which has traditionally been administered intravenously. This new oral formulation aims to improve patient compliance and potentially lower healthcare costs related to long-term intravenous treatments. Intract Pharma Ltd., based in the UK, specializes in the development of infliximab-based treatments.

The key company operating in the remicade market is Janssen Biotech Inc.

North America was the largest region in the remicade market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in remicade report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the remicade market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The remicade market consists of sales of biosimilars of remicade, combination therapy products, administration tools, and packaging formats. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Remicade Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on remicade market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for remicade ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The remicade market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Disease Indication: Crohn's disease; Rheumatoid arthritis; Ankylosing spondylitis; Psoriatic arthritis; Ulcerative Colitis; Plaque psoriasis
• 2) By Route Of Administration: Subcutaneous; Intravenous; Parenteral
• 3) By End Use: Hospitals; Clinics; Ambulatory Care; Home Care
• Companies Mentioned: Janssen Biotech Inc.
• Countries: Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Remicade Market Characteristics

3. Remicade Market Biologic Drug Characteristics

• 3.1. Molecule Type
• 3.2. Route Of Administration (ROA)
• 3.3. Mechanism Of Action (MOA)
• 3.4. Safety And Efficacy

4. Remicade Market Trends And Strategies

5. Remicade Market -Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

6. Global Remicade Growth Analysis And Strategic Analysis Framework

• 6.1. Global Remicade PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 6.2. Analysis Of End Use Industries
• 6.3. Global Remicade Market Growth Rate Analysis
• 6.4. Global Remicade Historic Market Size and Growth, 2019 - 2024, Value ($ Million)
• 6.5. Global Remicade Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Million)
• 6.6. Global Remicade Total Addressable Market (TAM)

7. Global Remicade Pricing Analysis & Forecasts

8. Remicade Market Segmentation

• 8.1. Global Remicade Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• Crohn's disease
• Rheumatoid arthritis
• Ankylosing spondylitis
• Psoriatic arthritis
• Ulcerative Colitis
• Plaque psoriasis
• 8.2. Global Remicade Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• Subcutaneous
• Intravenous
• Parenteral
• 8.3. Global Remicade Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• Hospitals
• Clinics
• Ambulatory Care
• Home Care

9. Global Remicade Epidemiology Of Clinical Indications

• 9.1. Drug Side Effects
• 9.2. Incidence And Prevalence of Clinical Indications

10. Remicade Market Regional And Country Analysis

• 10.1. Global Remicade Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• 10.2. Global Remicade Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

11. Asia-Pacific Remicade Market

• 11.1. Asia-Pacific Remicade Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Remicade Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• 11.3. Asia-Pacific Remicade Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• 11.4. Asia-Pacific Remicade Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

12. China Remicade Market

• 12.1. China Remicade Market Overview
• 12.2. China Remicade Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Million
• 12.3. China Remicade Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Million
• 12.4. China Remicade Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Million

13. India Remicade Market

• 13.1. India Remicade Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• 13.2. India Remicade Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• 13.3. India Remicade Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

14. Japan Remicade Market

• 14.1. Japan Remicade Market Overview
• 14.2. Japan Remicade Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• 14.3. Japan Remicade Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• 14.4. Japan Remicade Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

15. Australia Remicade Market

• 15.1. Australia Remicade Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• 15.2. Australia Remicade Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• 15.3. Australia Remicade Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

16. South Korea Remicade Market

• 16.1. South Korea Remicade Market Overview
• 16.2. South Korea Remicade Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• 16.3. South Korea Remicade Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• 16.4. South Korea Remicade Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

17. Western Europe Remicade Market

• 17.1. Western Europe Remicade Market Overview
• 17.2. Western Europe Remicade Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• 17.3. Western Europe Remicade Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• 17.4. Western Europe Remicade Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

18. UK Remicade Market

• 18.1. UK Remicade Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• 18.2. UK Remicade Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• 18.3. UK Remicade Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

19. Germany Remicade Market

• 19.1. Germany Remicade Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• 19.2. Germany Remicade Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• 19.3. Germany Remicade Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

20. France Remicade Market

• 20.1. France Remicade Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• 20.2. France Remicade Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• 20.3. France Remicade Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

21. Eastern Europe Remicade Market

• 21.1. Eastern Europe Remicade Market Overview
• 21.2. Eastern Europe Remicade Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• 21.3. Eastern Europe Remicade Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• 21.4. Eastern Europe Remicade Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

22. North America Remicade Market

• 22.1. North America Remicade Market Overview
• 22.2. North America Remicade Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• 22.3. North America Remicade Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• 22.4. North America Remicade Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

23. USA Remicade Market

• 23.1. USA Remicade Market Overview
• 23.2. USA Remicade Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• 23.3. USA Remicade Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• 23.4. USA Remicade Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

24. Canada Remicade Market

• 24.1. Canada Remicade Market Overview
• 24.2. Canada Remicade Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• 24.3. Canada Remicade Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• 24.4. Canada Remicade Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

25. South America Remicade Market

• 25.1. South America Remicade Market Overview
• 25.2. South America Remicade Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• 25.3. South America Remicade Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• 25.4. South America Remicade Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

26. Middle East Remicade Market

• 26.1. Middle East Remicade Market Overview
• 26.2. Middle East Remicade Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• 26.3. Middle East Remicade Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• 26.4. Middle East Remicade Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

27. Africa Remicade Market

• 27.1. Africa Remicade Market Overview
• 27.2. Africa Remicade Market, Segmentation By Disease Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• 27.3. Africa Remicade Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million
• 27.4. Africa Remicade Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million

28. Remicade Market Competitive Landscape And Company Profiles

• 28.1. Remicade Market Competitive Landscape
• 28.2. Remicade Market Company Profiles
  • 28.2.1. Janssen Biotech Inc. Overview, Products and Services, Strategy and Financial Analysis

29. Global Remicade Market Pipeline Analysis

• 29.1. High Level Clinic Trail Information

30. Global Remicade Market Competitive Benchmarking And Dashboard

31. Key Mergers And Acquisitions In The Remicade Market

32. Recent Developments In The Remicade Market

33. Remicade Market High Potential Countries, Segments and Strategies

• 33.1 Remicade Market In 2029 - Countries Offering Most New Opportunities
• 33.2 Remicade Market In 2029 - Segments Offering Most New Opportunities
• 33.3 Remicade Market In 2029 - Growth Strategies
  • 33.3.1 Market Trend Based Strategies
  • 33.3.2 Competitor Strategies

34. Appendix

• 34.1. Abbreviations
• 34.2. Currencies
• 34.3. Historic And Forecast Inflation Rates
• 34.4. Research Inquiries
• 34.5. The Business Research Company
• 34.6. Copyright And Disclaimer